
SANTA CRUZ BIOTECHNOLOGY, INC.

LOC643008 (T-14): sc-247697



BACKGROUND

LOC643008, also known as C17orf109 (chromosome 17 open reading frame 109), is a 77 amino acid single-pass membrane protein. The gene that encodes LOC643008 consists of approximately 7,973 bases and maps to human chromosome 17q25.1. Encoding more than 1,200 genes, chromosome 17 comprises over 2.5% of the human genome. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of ovary, colon, prostate gland and fallopian tubes.

REFERENCES

- 1. Hall, J.M., et al. 1992. Closing in on a breast cancer gene on chromosome 17q. Am. J. Hum. Genet. 50: 1235-1242.
- Evans, S.C. and Lozano, G. 1997. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol. Med. Today 3: 390-395.
- Varley, J.M., et al. 1997. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14: 865-871.
- Kersemaekers, A.M., et al. 1998. Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. Br. J. Cancer 77: 192-200.
- Soussi, T., et al. 2000. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum. Mutat. 15: 105-113.
- Piura, B., et al. 2001. Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier. Eur. J. Obstet. Gynecol. Reprod. Biol. 97: 241-244.
- 7. Minamoto, T., et al. 2001. Distinct pattern of p53 phosphorylation in human tumors. Oncogene 20: 3341-3347.

CHROMOSOMAL LOCATION

Genetic locus: SMIM5 (human) mapping to 17q25.1.

SOURCE

LOC643008 (T-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the N-terminus of LOC643008 of human origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-247697 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

LOC643008 (T-14) is recommended for detection of LOC643008 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for LOC643008 siRNA (h): sc-105776, LOC643008 shRNA Plasmid (h): sc-105776-SH and LOC643008 shRNA (h) Lentiviral Particles: sc-105776-V.

Molecular Weight of LOC643008: 9 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo-rescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.